Skip to main content

Table 1 Baseline characteristics

From: Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

 

All patients N = 119 (%)

IB CR + PR N = 69 (%)

IB SD N = 35 (%)

IB PD N = 15 (%)

p value

Median age at diagnosis in years (range)

64 (23–90)

66 (23–90)

63 (40–86)

64 (38–89)

0.67

Median age at ibrutinib therapy in years (range)

68 (27–91)

69 (27–90)

67 (42–86)

65 (41–91)

0.74

Gender

    

0.89

 Male

55 (46)

33 (48)

15 (43)

7 (47)

 

 Female

64 (54)

36 (52)

20 (57)

8 (53)

 

BMI

    

0.95

  < 30

71 (71)

43 (72)

20 (69)

8 (73)

 

  ≥ 30

29 (29)

17 (28)

9 (31)

3 (27)

 

 Missing

19

9

6

4

 

ECOG PS at diagnosis

    

0.53

 0

46 (46.5)

25 (42)

13 (50)

8 (61)

 

 1

47 (47.5)

32 (53)

11 (42)

4 (31)

 

  ≥ 2

6 (6)

3 (5)

2 (8)

1 (8)

 

Missing

20

9

9

2

 

MZL subtype

    

0.97

 NMZL

50 (42)

28 (41)

17 (49)

5 (33)

 

 SMZL

29 (24)

17 (25)

8 (23)

4 (27)

 

 EMZL

40 (34)

24 (34)

10 (28)

6 (40)

 

Stage at diagnosis

    

0.95

 1–2

19 (17)

11 (16)

6 (18)

2 (14)

 

 3–4

96 (83)

56 (84)

28 (82)

12 (86)

 

 Missing

4

2

1

1

 

B symptoms at diagnosis

    

0.62

 No

81 (74)

44 (70)

25 (78)

12 (80)

 

 Yes

29 (26)

19 (30)

7 (22)

3 (20)

 

 Missing

9

6

3

0

 

LDH higher than institutional baseline

    

0.80

 No

70 (71)

43 (71)

20 (74)

7 (64)

 

 Yes

29 (29)

18 (29)

7 (26)

4 (36)

 

 Missing

20

8

8

4

 

Albumin at diagnosis

    

0.75

 Normal

80 (81)

49 (80)

22

9

 

 Low

19 (19)

12 (20)

4

3

 

 Missing

20

8

9

3

 

Monoclonal protein at diagnosis

    

0.05

 No

49 (56)

30 (54)

17 (74)

2 (25)

 

 Yes

38 (44)

26 (46)

6 (26)

6 (75)

 

 Missing

32

13

12

7

 

BM involvement at diagnosis

    

0.72

 No

32 (32)

17 (30)

10 (33)

5 (42)

 

 Yes

67 (68)

40 (70)

20 (67)

7 (58)

 

 Not done

20

11

5

3

 

TP53 mutation/17p deletion (n = 67)*

    

0.99

 No

19 (28)

10 (23)

7 (47)

2 (25)

 

 Yes

10 (15)

7 (16)

2 (13)

1 (13)

 

 Unavailable/not tested

38 (57)

27 (61)

6 (40)

5 (62)

 

Complex cytogenetics (n = 67)*

    

0.16

 No

57 (85)

37 (90)

17 (85)

6 (67)

 

 Yes

10 (15)

4 (10)

3 (15)

3 (33)

 

Primary refractory disease**

    

0.07

 No

89 (75)

56 (81)

25 (71)

8 (53)

 

 Yes

30 (25)

13 (19)

10 (29)

7 (47)

 

First-line therapy

    

0.47

 Rituximab

58 (49)

35 (51)

19 (54)

4 (27)

 

 BR

30 (25)

16 (23)

9 (26)

5 (33)

 

 R-CVP

11 (9)

7 (10)

1 (3)

3 (20)

 

 R-CHOP

9 (8)

5 (7)

2 (6)

2 (13)

 

 Others

11 (9)

6 (9)

4 (11)

1 (7)

 

Receipt of maintenance R

    

0.27

 No

88 (74)

47 (68)

29 (83)

12 (80)

 

 Yes

31 (26)

22 (32)

6 (17)

3 (20)

 

Line of ibrutinib therapy

    

0.40

 Second line

54 (45)

31 (45)

16 (46)

7 (47)

 

 Third line

41 (35)

27 (39)

9 (26)

5 (33)

 

 Fourth line and beyond

24 (20)

11 (16)

10 (28)

3 (20)

 

 Median f/up in months (range)^

23 (1–75)

23 (1–72)

26 (3–75)

6 (3–22)

 
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, MZL marginal zone lymphoma, LDH lactate dehydrogenase, BM bone marrow, BR bendamustine rituximab, R-CVP rituximab, cyclophosphamide, vincristine, prednisone, R-CHOP rituximab, cyclophosphamide, Adriamycin, vincristine, prednisone, f/up follow-up
  2. *Only among those who had bone marrow involvement. Complex karyotype was defined as the presence of at least three chromosomal aberrations in at least two cells
  3. **Primary refractory disease: defined as progression of disease at the end of induction therapy or within 6 months of treatment completion. Among these 30 patients, 13 received rituximab, 9 received BR, 4 received R-CHOP, 3 received R-CVP, 1 received other
  4. ^Among those who are alive